Ashwagandha formulations differed in blood exposure, with health benefits still untested
In fasting healthy adults, a single Zenroot dose produced greater measured exposure to withanolides, compounds in ashwagandha, than reference formulations. This comparison did not test stress relief or other health benefits.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
Among healthy adults taking single doses while fasting, Zenroot produced higher measured blood exposure to total withanolides than the reference products. This was a formulation-specific absorption comparison, not a test of symptom improvement. The result cannot establish that a lower dose gives better health outcomes, and the authors call for studies that actually evaluate those benefits.
Single-dose blood measurements cannot establish effects during repeated use or long-term safety. Although Zenroot was described as well tolerated, the abstract supplies no detailed adverse-event results or numerical confidence limits for the reported bioavailability ratios.
What researchers found
Measured blood exposure after a single dose
With sampling through 24 hours, Zenroot 125 mg had reported bioavailability 2.1-fold higher than the 600 mg reference and 1.3-fold higher than the 500 mg reference.
What bioavailability means here
The researchers measured withanolides in blood after each formulation. Bioavailability describes the availability of these compounds after ingestion. It is a different endpoint from feeling less stressed, sleeping better or experiencing a clinical health improvement.
Why the comparison stays product-specific
The products differed in formulation, stated concentration and dose. The reported blood-exposure differences therefore describe these particular products under fasting conditions. They do not establish a general rule that less ashwagandha is more effective.
The original publication
Superior Bioavailability of a Novel 1.5% Ashwagandha Formulation (Zenroot™): A Randomized, Double-Blind, Single-Dose, Comparative, Oral Bioavailability Study in Healthy Adults.
Ramapalaniappan A, Loganathan V, Morde A et al.
Adv Ther · 2025
- PubMed ID
- 40748423
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.